Educational scope notice: This is a study note for medical students, not medical advice, diagnosis, or treatment guidance. Clinical management should follow local protocols and current guidelines.
Testing follows localization. The major task in evaluating a hypotonic neonate is determining whether the pathology sits above the anterior horn cell (central) or in the lower motor unit (peripheral), because each branch orders different tests. The central branch runs through neuroimaging, EEG, and metabolic or genetic testing. The peripheral branch runs through creatine kinase (CK), targeted blood genetics, nerve conduction studies with electromyography (NCS/EMG), and muscle biopsy.
Exclude acute central and systemic causes first
In neonatal series, central causes account for roughly two-thirds of cases, with hypoxic-ischemic encephalopathy (HIE) the most common single cause. This proportion comes from regional data and predates broad genomic testing, so treat it as orientation rather than a constant. The practical consequence stands: excluding acute central and systemic causes such as HIE, sepsis, and hypoglycaemia is the first move.
First-line blood tests when the picture is peripheral
When the examination points peripherally, targeted blood tests come before any invasive study. First-line peripheral investigations are CK, DNA testing for myotonic dystrophy, SMN1 gene-deletion testing, an EDTA blood sample for Prader-Willi testing, and chest radiograph with echocardiography to look for cardiomegaly or cardiomyopathy, plus microarray CGH.
SMN1 deletion testing is high-yield because the deletion is present in 95% of cases of spinal muscular atrophy type 1. This figure is scoped to type 1 and does not generalize to all spinal muscular atrophy. A positive SMN1 result settles the diagnosis, and invasive neurophysiology then adds nothing.
Read CK with a repeat-if-high rule
CK needs cautious interpretation in the newborn. Levels tend to be higher at birth, rise across the first 24 hours, and increase with acidosis. A high initial value therefore proves nothing on its own and should be repeated. No numeric cutoff defines myopathy here.
Keep NCS, EMG, and biopsy second-line
NCS/EMG can separate neurogenic, myopathic, myotonic, and myasthenic patterns, but the study is difficult in the first 6 months of life. Muscle biopsy goes to histology, immunohistochemistry, electron microscopy, and respiratory-chain analysis as a second-line step. Two stopping rules govern both: positive blood genetics obviate biopsy, and a normal early EMG does not exclude disease.
Evidence anchors
- Evaluation of the floppy infant. NHS Greater Glasgow and Clyde Paediatric Clinical Guidelines: https://www.clinicalguidelines.scot.nhs.uk/ggc-paediatric-guidelines/ggc-paediatric-guidelines/neonatology/evaluation-of-the-floppy-infant
- Ahmed MI, Iqbal M, Hussain N. A structured approach to the assessment of a floppy neonate. J Pediatr Neurosci. 2016;11(1):2-6: https://pmc.ncbi.nlm.nih.gov/articles/PMC4862282/